| Inebilizumab is a humanized, immunoglobulin G1κ monoclonal antibody that binds to CD19, resulting in effective depletion of peripheral B cells. |
| The pharmacokinetics of inebilizumab were adequately described by a two-compartment model with parallel first-order and time-dependent nonlinear elimination pathways. |
| Common covariates had no clinically relevant impact on the pharmacokinetics of inebilizumab. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.